| ID | 1379 | |
| PMID | 21291377 | |
| Year | 2011 | |
| Sequence | CDLPQTHSLGSRRTLM LLAQMRKISLFSCLKD RHDFGFPQEEFGNQFQ KAETIPVLHEMIQQIF NLFSTKDSSAAWDETL LDKFYTELYQQLNDLE ACVIQGVGVTETPLMK EDSILAVRKYFQRITL YLKEKKYSPCAWEVVR AEIMRSFSLSTNLQES LRSKE | |
| Name | Interferon Alpha (IFN α) | |
| Length | 165 | |
| N-Terminal Modification | Free | |
| C-Terminal Modification | Free | |
| Linear/ Cyclic | Cyclic (C1-C98, C29-138) | |
| Chirality | L | |
| Chemical Modification | Gylcosylation at 82th residue | |
| Origin of Peptide | Interferon Alpha (IFN α) | |
| Nature of Peptide/Cargo | Antiviral, antiproliferative, and immunomodulatory properties | |
| Mechanism | Not mentioned | |
| Cargo Sequence/Structure | None | |
| Name of cargo | Not applicable | |
| Assay | ELISA and antiviral assay | |
| Enhancer | Topical reservoir-type round patches were used for transdermal delivery. Biphasic vesicles preparations with 0, 5, 15, or 40MIU IFN α were placed into the cavity of the patch. | |
| Properties of enhancer | Not mentioned | |
| Concentration | 40 MIU IFN α | |
| Incubation time | 48 hours | |
| Tissue permeability (value with units) | Antiviral assay showed an average IFN α levels of 400±80 IU/mg protein in skin homogenate. ELISA of skin homogenate increased the IFNα levels from <12.5pg/mg tissue to 107.5±18.1 pg/mg tissue. | |
| Tissue Sample | Human skin biopsy samples | |
| Ex vivo/In vivo/In vitro | in vivo | |
| STRUCTURE |
| |
| SMILES | N.A. | |